Original Research

Page 13

JCP
Toward A Definition Of “No Meaningful Benefit” From Antidepressant Treatment
JCP
Nocturnal Wakefulness and Suicide
JCP
Association of Bupropion and Opioid Use Disorder Medications With Stimulant-Related Admissions
PCC
Social Anxiety Among Lebanese Adolescents
JCP
Mental Pain, Suicide Risk, and Childhood Trauma
JCP
Maternal Postnatal Depression and Infant Immunizations
JCP
Predictors of Suicidality After Psychiatric Hospitalization
PCC
Vortioxetine Supratherapeutic Dosing in TRD
JCP
Pregnancy Outcomes With First-Trimester SGA Exposure
PCC
Cholesterol, Obesity, and Metabolic Syndrome in Epileptic Patients
JCP
Transdermal HP-3070 for Hostility in Schizophrenia
JCP
Suicide Risk in a National VA Sample
JCP
Long-term Outcomes of Early Use of LAIs in Schizophrenia
PCC
Sleep in Older Adults During the COVID-19 Pandemic
JCP
Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in MDD
PCC
COVID Vaccination Among Patients With Severe Mental Illness
PCC
Attachment Styles and Mental Health in Adolescents
JCP
Clozapine Use in Singapore and Hong Kong
JCP
Youth Aware of Mental Health (YAM) Intervention
JCP
Eating Disorders in Youth With Bipolar Disorder
JCP
Antipsychotic Efficacy of KarXT (Xanomeline−Trospium)
Original Research

image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ May 11, 2022

This post hoc analysis of phase 2 data evaluated rates and time course of response with the new combination oral agent KarXT (xanomeline−trospium) in the treatment of schizophrenia.
PCC
Social and Emotional Health of College Students and COVID-19
JCP
Daily Dose Effects of Risperidone on Metabolic Parameters
PCC
Resilience, Coping, Distress, and COVID-19